Patient education conversations emphasize 3 core elements: equivalent efficacy supported by rigorous pharmacokinetic and ...

Head and neck cancers rank 6th in newly diagnosed cases and 7th in newly reported cancer deaths worldwide. Head and neck squamous cell carcinoma (HNSCC) constitutes the majority of these malignancies.

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. In a recent update, Bristol-Myers ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...

Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

The efficacy of nivolumab plus ipilimumab compared with chemotherapy alone was evaluated through a meta-analysis, 1 using HRs to determine the efficacy. A random-effects model was utilized to pool all ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.